News | August 02, 2012

ROMICAT II Trial Shows CT Angiography Improves Efficiency of Care in Evaluating Chest Pain

August 2, 2012 — Results of the ROMICAT II trial indicates coronary computed tomography (CT) angiography (CCTA) as a safe and time-efficient noninvasive modality to evaluate patients with chest pain in the emergency department (ED) when compared to the current standard approach.

ROMICAT II (Rule Out Myocardial Ischemia/Infarction Using Computer Assisted Tomography) is a multicenter randomized comparative effectiveness trial of CCTA versus standard triage evaluation in acute chest pain patients in the ED. The study, lead by Udo Hoffmann, M.D., from the Massachusetts General Hospital, examines whether integrating CCTA improves the efficiency of the management of low-intermediate risk patients. The trial involved 1000 patients who entered the ED with chest pain and, after initial evaluation, were randomly assigned to either a CCTA scan or to standard triage evaluation.

Results indicated that patients diagnosed with a CT scan reduced their mean average time spent in the hospital by 7.6 hours. Fifty percent of patients receiving the CCTA scan were safely discharged within nine hours, while only 15 percent of patients receiving standard of care as a diagnosis were discharged in that time period. The reduced time produced an ED cost savings for the CCTA group of 18 percent, compared to the standard of care diagnosis ($2,101 vs. $2,566). However, the mean cost of care, including hospital stay, was similar between both groups ($4,026 vs. $3,874). Long-term cost data was not available which would allow determining whether negative CCTA results would allow fewer repeat visits to the ED and hospitalizations over a longer time period.

One critical piece of information that may have not been emphasized enough is that the rate of adverse cardiovascular events (MACE) at 28 days in the standard of care ED evaluation was 1.2 percent (including four myocardial infarctions [MI] and two cases of unstable angina for which percutaneous coronary intervention [PCI] was required). The CCTA approach had only two events (0.4 percent) at 28 days; however, in both cases CCTA established correctly clinically significant coronary artery disease (CAD) during the initial hospitalization, but both patients had negative stress tests and were initially treated medically. It is important to emphasize that the 1.2 percent rate of MACE in the standard of care group is above the "acceptable" rate (<1 percent) of missing a patient with acute coronary syndrome in the ED setting.

While the randomized comparison in this study showed increased cumulative radiation dose in the CCTA group, it is important to emphasize that nearly all patients in the CCTA group (97 percent), but only 33 percent of patients randomly assigned to standard evaluation, were exposed to radiation from an imaging test or procedure. The mean radiation dose from CCTA (11.3±5.3 mSv) was lower than single photon emission CT (14.1±4.8 mSv, P<0.001). Nowadays diagnostic-quality CCTA can be performed routinely in clinical practice with doses of less than 5 mSv. SCCT highly recommends and promotes the use of radiation dose reduction techniques in clinical practice.

"This study adds to the growing body of evidence that assessment of low- to intermediate-risk patients with CCTA improves efficiency in the ED. Because it is highly accurate in selecting those without coronary disease, this test also removes the uncertainty that patients and physicians alike often continue to feel after these patients are evaluated with the standard approach to acute chest pain," said John Lesser, president of SCCT.

"The results of the ROMICAT II trial support prior available evidence from two other large randomized trials (ACRIN-PA and CT-STAT) confirming the safety of a negative CTA to discharge patients, leading to decreased length of stay and potential cost savings. Cautious implementation of this modality in the ED setting is needed to ensure proper patient selection and preparation, implementation of radiation dose reduction techniques, and assurance of available expertise and coverage," said Ricardo C. Cury, chairman of radiology and director of cardiac imaging, Baptist Hospital of Miami and Baptist Cardiac and Vascular Institute.

For more information: www.scct.org

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init